794 related articles for article (PubMed ID: 10606960)
1. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
[TBL] [Abstract][Full Text] [Related]
2. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule.
McLellan AD; Starling GC; Williams LA; Hock BD; Hart DN
Eur J Immunol; 1995 Jul; 25(7):2064-8. PubMed ID: 7542604
[TBL] [Abstract][Full Text] [Related]
3. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions.
Greene JL; Leytze GM; Emswiler J; Peach R; Bajorath J; Cosand W; Linsley PS
J Biol Chem; 1996 Oct; 271(43):26762-71. PubMed ID: 8900156
[TBL] [Abstract][Full Text] [Related]
4. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.
Linsley PS; Greene JL; Brady W; Bajorath J; Ledbetter JA; Peach R
Immunity; 1994 Dec; 1(9):793-801. PubMed ID: 7534620
[TBL] [Abstract][Full Text] [Related]
5. In situ expression of B7 and CD28 receptor families in human malignant melanoma: relevance for T-cell-mediated anti-tumor immunity.
Denfeld RW; Dietrich A; Wuttig C; Tanczos E; Weiss JM; Vanscheidt W; Schöpf E; Simon JC
Int J Cancer; 1995 Jul; 62(3):259-65. PubMed ID: 7543078
[TBL] [Abstract][Full Text] [Related]
6. Effect of CD80 and CD86 on T cell cytokine production.
Petro TM; Chen SS; Panther RB
Immunol Invest; 1995 Nov; 24(6):965-76. PubMed ID: 8575841
[TBL] [Abstract][Full Text] [Related]
7. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells.
Caux C; Vanbervliet B; Massacrier C; Azuma M; Okumura K; Lanier LL; Banchereau J
J Exp Med; 1994 Nov; 180(5):1841-7. PubMed ID: 7525840
[TBL] [Abstract][Full Text] [Related]
8. Blocking CD40 - CD154 and CD80/CD86 - CD28 interactions during primary allogeneic stimulation results in T cell anergy and high IL-10 production.
Van Gool SW; Vermeiren J; Rafiq K; Lorr K; de Boer M; Ceuppens JL
Eur J Immunol; 1999 Aug; 29(8):2367-75. PubMed ID: 10458748
[TBL] [Abstract][Full Text] [Related]
9. Costimulatory molecules in Wegener's granulomatosis (WG): lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cells.
Moosig F; Csernok E; Wang G; Gross WL
Clin Exp Immunol; 1998 Oct; 114(1):113-8. PubMed ID: 9764612
[TBL] [Abstract][Full Text] [Related]
10. Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28.
Peach RJ; Bajorath J; Naemura J; Leytze G; Greene J; Aruffo A; Linsley PS
J Biol Chem; 1995 Sep; 270(36):21181-7. PubMed ID: 7545666
[TBL] [Abstract][Full Text] [Related]
11. Low CD86 expression in the nonobese diabetic mouse results in the impairment of both T cell activation and CTLA-4 up-regulation.
Dahlén E; Hedlund G; Dawe K
J Immunol; 2000 Mar; 164(5):2444-56. PubMed ID: 10679081
[TBL] [Abstract][Full Text] [Related]
12. T helper-independent activation of human CD8+ cells: the role of CD28 costimulation.
Van Gool SW; Zhang Y; Kasran A; de Boer M; Ceuppens JL
Scand J Immunol; 1996 Jul; 44(1):21-9. PubMed ID: 8693288
[TBL] [Abstract][Full Text] [Related]
13. Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86.
Lane P
Ann N Y Acad Sci; 1997 Apr; 815():392-400. PubMed ID: 9186685
[TBL] [Abstract][Full Text] [Related]
14. Expression of the costimulator molecules, CD80, CD86, CD28, and CD152 on lymphocytes from neonates and young children.
Elliott SR; Macardle PJ; Roberton DM; Zola H
Hum Immunol; 1999 Nov; 60(11):1039-48. PubMed ID: 10600000
[TBL] [Abstract][Full Text] [Related]
15. Expression and function of CD80 and CD86 costimulator molecules on synovial dendritic cells in chronic arthritis.
Summers KL; O'Donnell JL; Williams LA; Hart DN
Arthritis Rheum; 1996 Aug; 39(8):1287-91. PubMed ID: 8702435
[TBL] [Abstract][Full Text] [Related]
16. CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy?
van Gool SW; Barcy S; Devos S; Vandenberghe P; Ceuppens JL; Thielemans K; de Boer M
Res Immunol; 1995; 146(3):183-96. PubMed ID: 8525052
[No Abstract] [Full Text] [Related]
17. Differential expression of costimulatory molecules in chronic inflammatory periodontal disease tissue.
Orima K; Yamazaki K; Aoyagi T; Hara K
Clin Exp Immunol; 1999 Jan; 115(1):153-60. PubMed ID: 9933436
[TBL] [Abstract][Full Text] [Related]
18. Enhanced expression of CTLA-4 (CD152) on CD4+ T cells in HIV infection.
Steiner K; Waase I; Rau T; Dietrich M; Fleischer B; Bröker BM
Clin Exp Immunol; 1999 Mar; 115(3):451-7. PubMed ID: 10193417
[TBL] [Abstract][Full Text] [Related]
19. Characterization of human inducible costimulator ligand expression and function.
Aicher A; Hayden-Ledbetter M; Brady WA; Pezzutto A; Richter G; Magaletti D; Buckwalter S; Ledbetter JA; Clark EA
J Immunol; 2000 May; 164(9):4689-96. PubMed ID: 10779774
[TBL] [Abstract][Full Text] [Related]
20. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry.
Ferenczi K; Burack L; Pope M; Krueger JG; Austin LM
J Autoimmun; 2000 Feb; 14(1):63-78. PubMed ID: 10648117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
